- Two cancer drugmaker rivals presented data on Monday about how combinations of their drugs, which harness the body's immune system to treat cancer, worked in treating a common form of lung cancer compared to traditional chemotherapy.
- Merck showed that its drug Keytruda in combination with chemotherapy cut the risk of death in lung cancer patients in half.
ADVERTISEMENT
2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)
The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.
ADVERTISEMENT
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT